"At PMV Pharmaceuticals, we are targeting the most frequently mutated gene in human cancer (p53) to make an unprecedented impact on cancer patients' lives. InterWest Healthcare Partners’ knowledge and understanding of transformative biology made them our ideal lead investor."
LeadershipDavid Mack, Co-Founder, President & CEO
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer and infectious disease. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.